OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas
Frederique MC Boonstra, Andrew Evans, Gustavo Noffs, Thushara Perera, Vilija Jokubaitis, Jim Stankovich, Adam P Vogel, Bradford A Moffat, Helmut Butzkueven, Scott C Kolbe, Anneke van der Walt
Multiple Sclerosis and Related Disorders | ELSEVIER SCI LTD | Published : 2020
BACKGROUND: Treatment of tremor in MS is an unmet need. OnabotulinumtoxinA (BoNT-A) has shown promising results; however, little is known regarding its effects on the brain. The clinical presentation of tremor MS is shown to depend on subcortical neural damage and cortical neural plasticity. This study aimed to identify effects of onabotulinumtoxinA (BoNT-A) on brain activation in MS and upper-limb tremor using functional MRI. METHODS: Forty-three MS participants with tremor were randomized to receive intramuscular injections of placebo (n = 22) or BoNT-A (n = 21). Tremor was quantified using the Bain score (0-10) for severity, handwriting and Archimedes drawing at baseline, 6 weeks and 12 w..View full abstract
Related Projects (1)
Awarded by NHMRC
This project was funded by an NHMRC Project Grant (1085461 CIA Van der Walt) and Fellowship (1135683 Vogel). The Bionics Institute receives Operational Infrastructure Support from the Victorian Government. NHMRC 1085461. Botox supplied in an unrestricted grant from Allergan Australia.